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Management of West syndrome is unsatisfactory. In our clinic we observed that a signifi-
cant proportion of patients respond to usual dose of valproate. Objective:To prospectively
assess the efficacy of valproate in controlling infantile spasms in West syndrome. Meth-
ods: Consecutive patients presenting withWest syndrome to the Pediatric Neurology Clinic
or general outpatient department (OPD) were enrolled for study. Those who were not on
any treatment were given valproate in a dose of 30 mg/kg/day while awaiting investiga-
tions. Patients were followed up every 2 weeks. Predefined criteria for definition of West
syndrome and response were used. Those showing partial/poor response or relapse on
valproate were given hormonal therapy. Results: One hundred children with West syn-
drome were enrolled. Ninety one children were started on valproate. Of these 36 (39.5%)
showed a good response, but seven later relapsed while on same dose of valproate and
three were lost to follow up. Later age at onset and typical hypsarrhythmia on EEG were
associated with good sustained response to valproate while a history of delayed cry at birth
was associated with partial or poor response. Sixty two patients who responded poorly to
or relapsed on valproate were put on hormonal treatment in addition. Of these 36 (58.1%)
had a good response but 11 later relapsed after stopping treatment and two were lost
to follow up. Conclusion: Valproate may have a role in treatment of West syndrome in a
selected group of patients.
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West syndrome is an age-dependent epileptic encephalopathy
characterized by the clinico-electrical triad of infantile epilep-
tic spasms, arrest, or regression of psychomotor development
and hypsarrhythmia, although the latter element may be miss-
ing (Lux and Osborne, 2004). Variants of this classical triad
comprise variations of age of onset, ranging from the first
month to 4 years; spasms that may be single, asymmetrical, or
combined with focal seizures; asymmetrical, synchronous, or
fragmented hypsarrhythmia; and psychomotor function which
may be delayed, deteriorated, or normal (Lux and Osborne,
2004).
West syndrome is the most common infantile epileptic syn-
drome seen in our Pediatric Neurology Clinic. In a study from
the All India Institute of Medical Sciences, New Delhi, it was the
commonest epileptic encephalopathy seen in the pediatric neurol-
ogy clinic (Kalra et al., 2002). The same is the experience at our
pediatric neurology clinic at the King George Medical University,
Lucknow.
Although West syndrome is a common epileptic syndrome, its
treatment is so far unsatisfactory. ACTH or oral steroids are two
commonly used drugs controlling epileptic spasms in about two-
thirds of patients within days of initiation, while vigabatrin is
especially useful in tuberous sclerosis associated West syndrome
(MacKay et al., 2004). However, a significant number of patients
relapse after discontinuation and no studies till date show conclu-
sively that any one treatment significantly improves the long-term
intellectual outcome of these infants (Hancock et al., 2009). There
are some studies on use of valproate in West syndrome (Bachman,
1982; Dyken et al., 1985; Seimes et al., 1988; Pratz et al., 1991;
Ohtsuka et al., 1992; Sharma, 2012). In our own Pediatric Neurol-
ogy Clinic we found that in a significant proportion of patients,
the spasms respond completely to usual dose of valproate while
awaiting investigations. We therefore embarked on a systematic
study on treatment of West syndrome to prospectively assess the
response to usual dose valproate and study factors predicting such
a response.
MATERIALS AND METHODS
SETTING
The study was conducted in the pediatric outpatient department
(OPD) and Pediatric Neurology Clinic of the King George Med-
ical University Hospital, Lucknow. Lucknow is the capital of the
state of Uttar Pradesh – India’s most populous state and also one
of the poorest. The King George Medical University Hospital is a
state run teaching hospital which caters to poor or seriously sick
patients from Lucknow city and the surrounding districts.
Children aged 1 month to 5 years attending either the general
pediatric OPD or the Pediatric Neurology Clinic were enrolled
for the study if they had infantile spasms and psychomotor retar-
dation or regression with or without hypsarrhythmia on EEG.
Acutely sick children, and those whose parents did not consent for
the study were excluded. Patients already receiving antiepileptic
drugs were enrolled but excluded from the comparison of fac-
tors predicting response to treatment. Socioeconomic status was
judged by the Kuppuswamy scale (Phatak, 1997). A history of peri-
natal asphyxia, low birth weight, and prematurity was taken from
medical records or if these were unavailable, by simply questioning
the mother and other family members.
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Enrolled patients were worked up according to a standardized
protocol. Details of history, examination, investigations, and fol-
low up were entered in predesigned data collection forms. A 16
channel EEG and neuroimaging (magnetic resonance imaging of
brain – 1.5 Tesla machine or cranial CT scan – as afforded by the
family) was obtained. Tests for developmental quotient (develop-
mental Assessment of Indian Infants – DASII; Malin, 1971) and
social quotient (Malin’s adaptation of Vineland Social Maturity
Scale; Matsuo et al., 2001) were administered by a trained child
psychologist initially and at the end of 6 months.
At the first visit, previously untreated patients were started on
valproate syrup in a dose of 30 mg/kg/day in three divided doses
while awaiting investigations.
FOLLOW UP
The patient was asked to keep a seizure dairy and recalled every
2 weeks. On each visit the number of series/day and number of
spasms per series was recorded. Note was made of occurrence of
any other types of seizures or relapse of infantile spasms.
Spasm Outcome was assessed as follows:
1. No reduction in spasms was considered as no response.
2. If spasms decreased by less than 50% after initiation of therapy,
it was considered as a poor response.
3. If spasms decreased by more than 50% but less than 80% after
initiation of therapy, it was considered as a partial response.
4. If spasms decreased by more than 80%, it was considered as
good response.
5. Complete cessation of spasms was classified as complete
response.
Response categories 1, 2, and 3 and those who relapsed after initial
good response were considered as partial or poor responders. In
these patients, valproate was continued in same doses and hor-
monal therapy was added. Response categories 4 and 5 were con-
sidered good responders if they did not relapse and were continued
on valproate alone. Hormonal treatment was in the form of daily
injection ACTH 40 units intramuscularly or oral prednisolone
2 mg/kg/day in 2–3 divided doses for 2 weeks. If spasms were con-
trolled within this period the ACTH or prednisolone was tapered
over the next 2 weeks. In case of partial or poor response these
medications were continued for a total of 4 weeks and then tapered.
The study had the approval of the Ethics Committee of King
George Medical University, Lucknow. Written informed consent
was taken from parents/guardians of the patient.
ANALYSIS
Patient and spasm characteristics were compared between respon-
ders and non-responders to arrive at factors associated with good
sustained response to valproate. The two sample t test was used for
comparing means and the Chi-square test was used for comparing
proportions.
RESULTS
A total of 100 patients were enrolled during the study period and
the clinical profile and demographic factors were studied in all.
The clinical profile and the demographic factors are described
in Table 1. The mean age of onset of spasms was 5.77 months
and the mean age of presentation of the patients to us was
14.97 months, mean delay in presentation being 9.29 months.
Adverse perinatal/neonatal events had occurred in almost three
fourth of the patients, while another 15% had a history of
adverse post-neonatal events (post-neonatal central nervous sys-
tem infection in eight and significant head injury in two). Classic
hypsarrhythmia was present in 1/3rd of cases only. Sequelae to
hypoxic ischemic encephalopathy (HIE) was the most common
abnormality detected on neuroimaging.
Of the 100 enrolled patients, nine were already on treatment,
so could not be given treatment according to the study protocol.
Table 1 | Descriptive data on 100 enrolled patients.
Factor No. of patients
Mean age at onset in months (SD) 5.77 (6.78)
Mean age at presentation in months (SD) 14.97 (10.84)
Mean delay in presentation in months (SD) 9.29 (8.85)
Male sex 77
Urban residence 46
Lower socio economic class 38
Upper socio economic class 4
Adverse perinatal/neonatal events 72
Assisted vaginal delivery 3
LSCS delivery 16
Preterm gestation 9
Low birth weight 27
Delayed timing of cry at birth 65
History of neonatal illness 52
Adverse post-neonatal events 15
TYPE OF SPASMS
Flexor spasms 85
Extensor spasms 9
Mixed spasms 6
Spasm occurrence in series 52
Associated features with spasms 57
Spasms mostly on awakening 81
ASSOCIATED FEATURES
Developmental delay at onset of seizures 88
Any dysmorphic feature 23
Microcephaly 55
Abnormal motor examination 73
Other seizure types at presentation 20
NEUROIMAGING (DONE IN 88 PATIENTS)
Normal 1/88 (1.1)
Atrophy 26/88 (29.5)
Encephalomalacia/sequel to HIE 27/88 (30.6)
Infarct/focal atrophy/scar 17/88 (19.3)
Malformation of brain 9/88 (10.2)
Hydrocephalus 8/88 (9.0)
EEG (DONE IN 95 PATIENTS)
Typical hypsarryhthmia 31/95 (32.6)
Generalized or multifocal spikes 38 (40.0)
Focal spikes 14 (14.7)
Burst suppression 6 (6.3)
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Thus, a total of 91 patients were put on valproate, while awaiting
investigations. Of these, 36 (39.5%) showed initial good response
(response categories 4 or 5), while 55 patients showed partial or
poor response. However of the 36, seven patients relapsed within
3 months on same dose of valproate, three were lost to follow
up, and only 26 (29.5%) patients continued to have a sustained
good response (Figure 1). Patients were followed up for at least
6 months. No significant adverse effects were noted and routine
monitoring of liver functions and valproate drug level was not
done. The reason for loss to follow up could not be ascertained as
these patients could not be contacted.
Clinical, demographic, and risk factors were compared in those
showing good (26 patients) and partial/poor response/relapse (62
patients) by univariate analysis to look for factors associated with
good sustained response to valproate (Table 2). Comparison of
means was done by ANOVA and comparison of proportions by
the Chi-Square test. Older age at onset of spasms (p= 0.021)
and typical hypsarrhythmia on EEG (p= 0.001) were found to
be significantly associated with a sustained good response to val-
proate therapy, while history of delayed cry at birth was associated
with a poor response (p= 0.040).
Patients who showed an initial partial/poor response to val-
proate, or later relapsed after initial good response were then put
on hormonal therapy in addition. A total of 62 children were put
on hormonal therapy, of which 36 (58.06%) showed good initial
response but of these 11 later relapsed after hormonal therapy was
discontinued and two patients were lost to follow up. So only 23/62
(37.1%) could be counted as having a sustained response to hor-
monal treatment (Figure 1). Children who showed partial/poor
response to hormonal therapy or those who relapsed were tried
on other antiepileptic drugs such as vigabatrin and lamotrigine.
DISCUSSION
The present study comprised of a relatively large number of
patients compared with some previous studies; 47 children by
Matsuo et al., 2001; Sharma and Vishwanthan, 2008), 26 children
FIGURE 1 | Showing enrollment of patients and outcomes.
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Table 2 | Comparison of patients who showed a sustained response to valproate with those who had partial/poor response or relapse.
Factors Partial/poor
response n=62 (%)
Good response
n=26 (%)
Odds ratio
(95% Confidence limits)
pValue
Mean age at onset (in months; SD)1 4.49 (4.46) 8.17 (10.44) – 0.021*
Mean age at presentation (in months) mean (SD)1 13.84 (9.18) 17.69 (15.29) – 0.149
Mean delay in presentation (in months) mean (SD)1 9.40 (8.68) 9.78 (10.15) – 0.858
Male sex2 55 (78.6) 17 (68.0) 0.55 (0.20–1.50) 0.181
Urban residence2 28 (45.1) 13 (50.0) 1.2 (0.4–3.3) 0.678
Hospital birth2 35 (56.4) 13 (50.0) 0.77 (0.3–2.1) 0.579
Adverse perinatal/neonatal events2 45 (72.5) 19 (73.0) 1.03 (0.3–3.3) 0.961
Preterm gestation2 5 (8.0) 2 (7.6) 0.95 (0.1–6.1) 1.000
LBW2 17 (27.4) 4 (15.3) 0.48 (0.1–1.8) 0.226
Delayed cry at birth2 43 (69.3) 12 (46.1) 0.38 (0.1–1.1) 0.040*
Neonatal illness2 30 (48.3) 16 (61.5) 1.71 (0.6–4.8) 0.259
Cryptogenic etiology2 4 (6.4) 5 (19.2) 3.45 (0.7–17.3) 0.117
Adverse post-neonatal events2 9 (14.5) 4 (15.3) 1.07 (0.2–4.4) 1.000
“Typical” infantile spasms2 42 (67.7) 19 (73.0) 1.3 (0.4–4.0) 0.620
Spasms in series2 33 (53.2) 14 (53.8) 1.03 (0.4–2.8) 0.957
Spasms mostly on awakening2 53 (85.4) 20 (76.9) 0.57 (0.2–2.1) 0.360
Normal motor development2 16 (25.8) 5 (19.2) 0.68 (0.2–2.3) 0.509
Normal mental development2 20 (32.2) 9 (34.6) 1.11 (0.4–3.2) 0.830
Normal social development2 20 (32.2) 11 (42.3) 1.54 (0.5–4.4) 0.367
Associated features
Developmental delay at onset of spasms2 48 (77.4) 20 (76.9) 0.97 (0.3–3.3) 0.959
Any dysmorphic feature2 17 (27.4) 4 (15.3) 0.5 (0.1–1.8) 0.255
Microcephaly2 32 (51.6) 12 (46.1) 0.8 (0.3–2.2) 0.640
Abnormal motor examination2 45 (72.5) 18 (69.2) 0.85 (0.3–2.6) 0.750
Other seizures at presentation2 14 (22.5) 6 (23.0) 1.03 (0.3–3.4) 0.959
Typical hypsarrhythmia on EEG (85/95)2 14/60 (23.3) 15/25 (60.0) 4.93 (1.6–15.2) 0.001*
Neuroimaging suggestive of HIE (n=82/88)2 24/59 (40.6) 6/23 (26.0) 0.51 (0.15–1.66) 0.217
1Comparison of means by ANOVA; figures indicate mean (SD).
2Comparison of proportions by chi-square test; figures indicate number of patients (%).
*Significant.
by Sharma and Vishwanthan, 2008; Goldstein and Slomski, 2008),
28 children by Goldstein and Slomski, 2008; Cohen-Sadan et al.,
2009). Criteria for definition of West syndrome were similar to
previous studies and hypsarrhythmia on EEG is not considered
essential for the diagnosis (Lux and Osborne, 2004). An in depth
study of all possible factors – demographic, clinical, and investiga-
tive, which can affect response to therapy was made. However, our
outcome was only seizure control rather than reversal of EEG fea-
tures and developmental outcome as these investigations could
not be repeated in the majority of our patients. Seizure con-
trol has been shown to correlate with improvement both of EEG
and development. Another limitation was the way study factors
were recorded. Since medical records are usually not available the
family’s word was taken at face value about “delayed cry,” low
birth weight etc. Further, this is an unblinded, uncontrolled, and
non-randomized study.
The mean age of onset was similar to that found in other stud-
ies. It was 5.77 months on an average compared with 5.5 months
in a previous study from Israel (Singhi and Ray, 2005) and
6.1± 3.4 months in an Indian study (Kalra and Passi, 1998). The
delay in presentation observed by us was also observed by other
Indian workers. We find that parents often do not realize that
the “startling” episodes are seizures. The pediatricians first seeing
these children have to specifically ask if the child “startles” with-
out any stimulus. Demographic and socioeconomic characteristics
may merely represent the profile of patients seen in our hospital.
Perinatal insults formed the major etiologic group compared with
antenatal and postnatal timing of insult. This has been the con-
clusion in many of the studies done previously (Kalra and Passi,
1998; MacKay et al., 2004; Tsuji et al., 2007).
The type of spasms were flexor in the majority. This was noted
by previous workers also. About 4/5th of patients had spasms
especially on awakening. However only slightly more than half
gave a typical history of spasms occurring in series. Such obser-
vations have not been remarked on in earlier studies. Lux and
Osborne (2004) categorized patients with spasms occurring singly
rather than in clusters as a separate group – infantile spasms single
spasm variant (ISSV). Associated developmental delay was present
in almost 90% of our patients while the rest had developmental
regression after onset of spasms. Other types of seizures at presen-
tation were present in 20% – very similar to the 31/165 (18.7%)
seen by Singhi and Ray (Kalra and Passi, 1998).
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Encephalomalacia/sequelae to perinatal hypoxic ischemic
encephalopathy was the major finding on neuroimaging seen
in 32.4% cases, the 2nd commonest finding being just atrophy.
Typical hypsarrhythmia was seen in a relatively small number of
patients (31.5%) as also seen by other Indian workers (Kalra and
Passi, 1998; Kalra et al., 2002; Tsuji et al., 2007). They however
qualified as West syndrome since developmental delay was present
in almost all the patients.
Availability of newer antiepileptic drugs has led to various treat-
ment regimens for West syndrome being tried all over the world,
topiramate (Peltzer et al., 2009), zonisamide (Yum and Ko, 2009),
pyridoxine (Auvichayapat et al., 2007), benzodiazepines (Sharma,
2012), lamotrigine (Gumus et al., 2007), and levetiracetam (Veg-
giotti et al., 1994). Some workers have tried high dose valproate
in West syndrome (Seimes et al., 1988; Pratz et al., 1991; Ohtsuka
et al., 1992; Sharma, 2012) in. However, the number of patients
treated in these studies was small. Seimes et al. (1988) using pro-
gressively higher doses of valproate could control spasms in 16 of
22 patients over a period of 6 months. We did not go on to high
dose valproate because we did not want to further delay starting
the “standard” treatment (hormonal). It is possible that higher
dosing may have produced a response in higher proportion of
patients.
We tried valproate initially in our patients only while they were
undergoing investigations. Patients were recalled every 2 weeks
and those who showed partial or poor response to valproate were
immediately shifted to the next line of therapy. An 80% response
in seizures was taken as meaningful because we feel that with a
lesser response, the physician would be prompted to use another
drug. Previous workers have taken a 50% or greater response in
seizures as a good response (Kalra et al., 2002).
Almost 2/5th of our patients had a good response to valproate
initially within 2 weeks but sustained response to valproate was
seen in less than 30%. Later age of onset was found to be associ-
ated with good sustained response to treatment. This was found
by Riikonen also (Lux et al., 2005). Hypsarrhythmia is usually
found early in the course of West syndrome, being later superceded
by other abnormalities. Atypical or asymmetric hypsarrhythmia
therefore may be associated with poor seizure control (Kalra et al.,
2002). A history of delayed cry often indicates perinatal asphyxia
and was the most common type of “symptomatic”West syndrome,
which carries a worse prognosis.
Efficacy of valproate has not been adequately studied in West
syndrome and no randomized controlled trial data is available
(Riikonen, 2010) although some earlier workers have found it to
be useful in high doses. In this relatively large study, we found
a favorable response in a significant proportion of patients even
with usual doses of valproate used alone. It must be borne in
mind that there may be completely different disease cohorts within
our patients with West syndrome, some of whom may respond
to valproate. We have tried to delineate this subset of patients
through this study. Proportion of initial responders who relapsed
were higher with hormonal therapy than with valproate (30.5 vs.
19.4%). Hence, with such a significant response to a relatively less
toxic drug, we feel that there is a case for further elucidating the
role of valproate in initial management of selected patients with
West syndrome through an appropriately powered randomized
controlled trial possibly in different dose ranges.
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